Can you take Denosumab with Treosulfan?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- denosumab
- treosulfan
Drug interactions
Moderate drug interactions
Moderate:
treosulfan denosumab
Applies to: treosulfan and denosumab
Using denosumab together with treosulfan can increase the risk of serious infections involving the skin, lower stomach area (abdomen), bladder, ear, or inner lining of the heart.
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
Contact your doctor immediately if you develop:
- fever or chills
- red, swollen skin or skin that is hot or tender to the touch
- itching or rash
- blisters
- severe abdominal pain
- frequent, urgent, or painful/burning urination
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
8 potential interactions Applies to: 7 conditions, including Seizures, Hypocalcemia, Hypoparathyroidism, Thyroid Disease, and Liver Disease.
Hypocalcemia
Major:
denosumab
Denosumab has a major potential interaction with Hypocalcemia.
Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.
Hypoparathyroidism
Major:
denosumab
Denosumab has a major potential interaction with Hypoparathyroidism.
Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.
Immunodeficiency
Moderate:
denosumab
Denosumab has a moderate potential interaction with Immunodeficiency.
Denosumab should be used with caution in patients with impaired immune systems or taking concomitant immunosuppressant agents as they may be at increased risk for serious infections.
Liver Disease
Moderate:
treosulfan
Treosulfan has a moderate potential interaction with Liver Disease.
Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.
Renal Dysfunction
Major:
denosumab
Denosumab has a major potential interaction with Renal Dysfunction.
Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.
Moderate:
treosulfan
Treosulfan has a moderate potential interaction with Renal Dysfunction.
Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.
Seizures
Moderate:
treosulfan
Treosulfan has a moderate potential interaction with Seizures.
There have been reports of seizures in patients following treatment with treosulfan. Patients should be monitored for signs of neurological adverse reactions, and clonazepam prophylaxis may be considered for patients at higher risk for seizures, including infants.
Thyroid Disease
Major:
denosumab
Denosumab has a major potential interaction with Thyroid Disease.
Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.
Report options
More resources
denosumab
A total of 324 drugs are known to interact with denosumab.
- Denosumab is in the drug class miscellaneous bone resorption inhibitors.
- Denosumab is used to treat the following conditions:
treosulfan
A total of 547 drugs are known to interact with treosulfan.
- Treosulfan is in the drug class alkylating agents.
- Treosulfan is used to treat Stem Cell Transplant Conditioning.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.